UNSPSC 51422362: Prednisolone phosphate

This classification denotes a therapeutic glucocorticoid with the molecular formula C21H29O8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 752SY38R6C, chemically known as pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-(phosphonooxy)-, (11.beta.)-, but more generally known as prednisolone phosphate, which bears US NIH Compound Identifier 4896. European Medicines Agency schedules prednisolone phosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10018MIG.

Most nations, for tariff purposes, schedule prednisolone phosphate under HS 29372100. SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COP(=O)(O)O)O)CCC4=CC(=O)C=C[C@]34C)O.

UNSPSC 51422362 Prednisolone phosphate is a Commodity code that describes a single pharmaceutical product — a corticosteroid medication — but the recent state and local opportunities tagged under this code show a mismatch with the code's nominal scope. The Seminole County, Florida opportunity (IFB60459723LAS, posted June 30, 2026) is actually soliciting naloxone and drug deactivation systems for community health initiatives, while the Texas Health and Human Services Commission RFI (HHS0017013, posted April 3, 2026) is exploring direct-to-manufacturer prescription contracting models for a Therapeutic Pharmacy Initiative. Neither opportunity involves prednisolone phosphate procurement. The code shows little relevant recent activity aligned with its defined pharmaceutical scope, and the tagged opportunities appear to reflect broader pharmaceutical supply, overdose-response, and pharmacy benefit management work rather than corticosteroid products specifically.

The geographic spread of recent activity under this code is limited to Florida and Texas, with Seminole County representing a health department buyer seeking annual deliveries of 1,900 units of naloxone and 800 safe drug deactivation systems through quarterly shipments to a central health facility, while the Texas HHS Commission is gathering market intelligence on vendor capabilities for direct manufacturer relationships before formal procurement follows. The mismatch between the code's pharmaceutical specification and the actual work being solicited suggests that either the tagging is incorrect or the code is being applied to capture broader pharmaceutical procurement activity. Business development professionals should verify whether their product or service aligns with prednisolone phosphate specifically before pursuing opportunities listed under this code.